RxDoctor Payments Data

Abdul Khan, MD

Internal Medicine · Pittsburgh, PANPI 1053349480

Payments from drug & device makers

$17,113in general payments, 2019–2025

Across 1,039 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$4K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Johnson & Johnson$911
  • AbbVie$874
  • plus $6K from 52 others

What the payments were for

  • Food & beverage$17,074100%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK214$3,732
Novo Nordisk191$2,303
AstraZeneca91$1,696
Lilly USA, LLC83$1,396
Johnson & Johnson40$911
AbbVie(2 entities)52$874
Pfizer53$750
Novartis49$743
Boehringer Ingelheim26$480
Abbott21$366
UCB, Inc.16$322
Amarin Pharma, Inc.17$303
E.r. Squibb & Sons, L.L.C.16$282
Bayer15$281
Amgen(2 entities)16$259
Exact Sciences11$234
Merck14$227
Dexcom, Inc.12$203
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$197
Vivus LLC8$133
Phathom Pharmaceuticals, Inc.6$131
Kowa Pharmaceuticals America, Inc.7$113
Nestle Healthcare Nutrition Inc.5$96
Valinor Pharma, LLC4$78
Otsuka America Pharmaceutical, Inc.3$68
Avanir Pharmaceuticals, Inc.5$63
Xeris Pharmaceuticals, Inc.3$52
Global Blood Therapeutics, Inc.3$51
Teva Pharmaceuticals USA, Inc.3$48
Paratek Pharmaceuticals, Inc.2$47
Shield Therapeutics Inc2$46
Vertical Pharmaceuticals, LLC3$44
Ultragenyx Pharmaceutical Inc.2$43
Astellas Pharma US Inc2$39
Hikma Pharmaceuticals USA2$36
Biohaven Pharmaceuticals, Inc.2$36
Sunovion Pharmaceuticals Inc.2$35
Sanofi-aventis U.S. LLC2$33
Arbor Pharmaceuticals, Inc.2$28
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$25
Insulet Corporation1$24
Neurelis, Inc.1$23
Azurity Pharmaceuticals, Inc.1$22
Almatica Pharma LLC1$22
Philips North America LLC1$21
Pulmonx Corporation1$20
Biohaven Pharmaceutical Holding Company Ltd.1$19
Corcept Therapeutics1$18
Nevro Corp.1$17
Esperion Therapeutics, Inc.1$17
Eisai Inc.1$17
Circassia Inc.1$16
Daiichi Sankyo Inc.1$13
Scilex Pharmaceuticals Inc.1$13
Sanofi Pasteur Inc.1$13
Tactile Systems Technology Inc1$13
Gilead1$11
Melinta Therapeutics, LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,113 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$123,785
Medicare patients
177
Services billed
1,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide300$362,749
Trelegy ElliptaFluticasone/Umeclidin/Vilanter255$259,873
EliquisApixaban316$224,675
Humira(Cf) PenAdalimumab11$153,067
XareltoRivaroxaban131$114,105
TrulicityDulaglutide78$88,852
MounjaroTirzepatide68$82,003
JardianceEmpagliflozin73$71,550
JanuviaSitagliptin Phosphate92$47,278
EntrestoSacubitril/Valsartan42$36,344
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog57$34,058
Lantus SolostarInsulin Glargine,hum.Rec.Anlog215$32,795
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr60$30,893
TradjentaLinagliptin20$26,853
Tresiba Flextouch U-200Insulin Degludec20$26,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,303$362,749300 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$3,732$317,019366 claims
PfizerEliquis$750$224,675316 claims
Lilly USA, LLCTrulicity, Mounjaro$1,396$170,855146 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Spiriva Respimat, Jentadueto$480$127,504127 claims
Johnson & JohnsonXarelto$911$114,105131 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,696$55,39188 claims
MerckJanuvia$227$47,27892 claims
NovartisEntresto$743$36,34442 claims
Astellas Pharma US IncMyrbetriq$39$21,82261 claims
Scilex Pharmaceuticals Inc.Colchicine$13$6,13672 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →